Emerson Electric In Talks To Acquire National Instruments For $8B: Report

Emerson Electric Co (NYSE: EMR) is reportedly in advanced talks to acquire National Instruments Corp (NASDAQ: NATI) after a long quest for the maker of measurement systems.
  • Emerson Electric Co (NYSE:EMR) is reportedly in advanced talks to acquire National Instruments Corp (NASDAQ:NATI) after a long quest for the maker of measurement systems.
  • Emerson is negotiating for $60 a share for the deal, which could value NATI at about $8 billion, Reuters reported citing familiar sources.
  • Emerson beat out rival Fortive Corp (NYSE:FTV) and Keysight Technologies Inc (NYSE:KEYS) in the run for National Instruments.
  • Following the announcement of Emerson’s interest in National Instruments in January, Reuters reported in March that Emerson, Fortive, and Keysight had advanced to the final round of bidding for the company.
  • Related: Emerson Discloses $7.6B Offer For National Instruments – Reveals Several Private Attempts Made Over Last Eight Months
  • Emerson had threatened to challenge National Instruments’ board of directors if it did not engage in deal negotiations in January, prompting the company to launch a formal sale process.
  • Emerson Electric held cash and equivalents of $2.27 billion as of Dec. 31, 2022.
  • Price Action: EMR shares are trading lower by 1.71% at $83.00 and NATI higher by 8.62% at $57.11 premarket on Wednesday.
Total
0
Shares
Related Posts
Read More

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.

INCY